| Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| MARCUS JOEL S | Director | Dec 19 | Sale | 50.82 | 5,000 | 254,100 | 29,233 | Dec 21 04:06 PM | | Mates Sharon | Chairman, President & CEO | Dec 13 | Sale | 55.00 | 33,083 | 1,819,565 | 1,100,309 | Dec 15 07:01 PM | | Halstead Michael | EVP and General Counsel | Dec 01 | Option Exercise | 15.47 | 50,000 | 773,500 | 50,000 | Dec 02 07:14 PM | | Halstead Michael | EVP and General Counsel | Dec 01 | Sale | 53.73 | 50,000 | 2,686,514 | 0 | Dec 02 07:14 PM | | MARCUS JOEL S | Director | Nov 07 | Sale | 52.30 | 10,000 | 523,023 | 34,233 | Nov 08 04:12 PM | | Hineline Lawrence J. | SVP of Finance CFO | Sep 21 | Option Exercise | 15.47 | 65,164 | 1,008,087 | 65,164 | Sep 23 09:01 PM | | Hineline Lawrence J. | SVP of Finance CFO | Sep 21 | Sale | 45.63 | 65,164 | 2,973,406 | 0 | Sep 23 09:01 PM | | VAN NOSTRAND ROBERT L | Director | Aug 11 | Option Exercise | 12.65 | 30,000 | 379,500 | 39,043 | Aug 12 06:09 PM | | VAN NOSTRAND ROBERT L | Director | Aug 11 | Sale | 57.13 | 30,000 | 1,713,975 | 9,043 | Aug 12 06:09 PM | | MARCUS JOEL S | Director | Aug 11 | Sale | 59.22 | 10,000 | 592,200 | 44,233 | Aug 12 06:05 PM | | MARCUS JOEL S | Director | May 12 | Sale | 55.00 | 10,000 | 550,000 | 54,233 | May 13 05:24 PM | | Neumann Mark | EVP, Chief Commercial Officer | Apr 08 | Option Exercise | 12.73 | 86,348 | 1,099,210 | 131,687 | Apr 08 06:56 PM | | Neumann Mark | EVP, Chief Commercial Officer | Apr 08 | Sale | 64.37 | 86,348 | 5,558,051 | 45,339 | Apr 08 06:56 PM | | RIGGS RORY B | Director | Mar 18 | Sale | 61.18 | 20,637 | 1,262,505 | 0 | Mar 18 08:12 PM | | RIGGS RORY B | Director | Mar 17 | Sale | 60.33 | 141,499 | 8,536,646 | 20,637 | Mar 18 08:12 PM | | RIGGS RORY B | Director | Mar 16 | Sale | 59.27 | 64,534 | 3,824,827 | 162,136 | Mar 18 08:12 PM | | Mates Sharon | Chairman, President & CEO | Mar 09 | Option Exercise | 2.84 | 38,925 | 110,547 | 1,133,392 | Mar 10 04:13 PM | | MARCUS JOEL S | Director | Mar 08 | Sale | 52.68 | 15,000 | 790,150 | 28,980 | Mar 09 09:49 PM | | MARCUS JOEL S | Director | Mar 07 | Sale | 54.52 | 5,000 | 272,600 | 43,980 | Mar 09 09:49 PM | | Durgam Suresh K. | Chief Medical Officer | Mar 04 | Sale | 55.52 | 3,860 | 214,307 | 23,104 | Mar 04 06:05 PM | | Durgam Suresh K. | Chief Medical Officer | Mar 02 | Sale | 56.98 | 4,177 | 238,005 | 26,964 | Mar 04 06:05 PM | | Halstead Michael | EVP and General Counsel | Feb 24 | Sale | 51.98 | 7,906 | 410,933 | 0 | Feb 25 07:06 PM | | Durgam Suresh K. | Chief Medical Officer | Feb 24 | Sale | 52.27 | 4,046 | 211,468 | 31,141 | Feb 25 07:09 PM | | Mates Sharon | Chairman, President & CEO | Feb 24 | Sale | 51.98 | 22,589 | 1,174,074 | 1,094,467 | Feb 25 07:01 PM | | Neumann Mark | EVP, Chief Commercial Officer | Feb 24 | Sale | 52.21 | 7,906 | 412,810 | 45,339 | Feb 25 07:08 PM | | Hineline Lawrence J. | SVP of Finance CFO | Feb 24 | Sale | 51.97 | 7,454 | 387,349 | 0 | Feb 25 07:04 PM | | Durgam Suresh K. | Chief Medical Officer | Feb 22 | Sale | 55.29 | 4,177 | 230,958 | 27,281 | Feb 23 07:08 PM | | Neumann Mark | EVP, Chief Commercial Officer | Feb 22 | Sale | 55.29 | 11,139 | 615,827 | 45,339 | Feb 23 07:07 PM | | Halstead Michael | EVP and General Counsel | Feb 22 | Sale | 55.40 | 11,139 | 617,100 | 0 | Feb 23 07:05 PM | | Hineline Lawrence J. | SVP of Finance CFO | Feb 22 | Sale | 55.40 | 10,443 | 578,506 | 0 | Feb 23 07:02 PM | | Mates Sharon | Chairman, President & CEO | Feb 22 | Sale | 55.39 | 27,847 | 1,542,413 | 1,094,467 | Feb 23 07:00 PM |
|
